A
Atreca
Precision Therapies from the Immune Response
About Atreca
Atreca, Inc. is a biotechnology company focused on developing novel antibody-based therapeutics for cancer and immune-related diseases. The company operates in the biopharmaceutical market, primarily serving healthcare providers and patients in need of advanced cancer treatments. Atreca's business model revolves around discovering, developing, and commercializing innovative therapies. The company generates revenue through strategic collaborations, licensing agreements, and public offerings of its common stock. Atreca's proprietary technology platform enables the identification of unique antibodies from the immune responses of cancer patients, which are then developed into therapeutic candidates. The company aims to address unmet medical needs by leveraging its expertise in antibody discovery and development.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2010
- Headquarters
- San Carlos, United States
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Bill & Melinda Gates Foundation
Mission Bay Capital
GSK- EAEvolution Corporate Advisors
Wellington Management
Cormorant Asset Management
Series B and later7 investors entered at this stage
Redmile Group
EcoR1 Capital
Boxer Capital- TMTekla Capital Management
Samsara BioCapital
Aisling Capital
Tavistock Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Atreca on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atreca on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.